Prevacid NapraPAC Scripts Suggest PPI/NSAID Combos May Thrive Post-Vioxx

TAP's Prevacid NapraPAC is among the early winners in the arthritis market following the withdrawal of Merck's Vioxx, IMS Health data suggest